Preclinical Research Services
We support your needs with customized solutions
Althea along with its strategic partner Dabur Research Foundation guides and operates the technical and scientific needs of global biotech companies and pharmaceutical developers during the preclinical phase of research. We provide a solid foundation of laboratory & drug development services, disease models and expertise.
Start a Project Services Overview
In 2008 we embarked on our mission in delivering specialized and integrated services to usher a rapidly evolving healthcare and wellness space in India. Since then, we have managed to bring on board some of the most innovative and promising healthcare firms in the country who share our vision in providing end to end services through a single, cohesive and reliable entity known today as the Althea DRF Lifesciences Group.
We support your needs with customized solutions
Our established scientific experience and customized, collaborative approach makes Althea the ideal partner for your company to achieve meaningful, high-quality, and fast results.
Together with Dabur Research Foundation, we provide scientific advice in selected therapeutic areas and a range of services easily adapted to your needs. With extensive experience in In Vitro, Ex-Vivo & In Vivo Pharmacology, Exploratory & GLP Toxicology & DMPK.
Visit our strategic partner website to know more : www.daburreseach.in
Our strong network of partners along with their specialized interests give us a unique positioning in the market, all leveraged through our own research and development infrastructure
Date: 28th March 2024
Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development.
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF Lifesciences, an established contract research organisation, aimed at combining the strengths of Partex's advanced AI & data services technology and Althea’s screening services and compounds.
The immediate scope of this exciting partnership is to provide end-to-end services from AI-driven drug discovery to wet lab validations to accelerate drug development.
Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative collaboration, stating, “We have been following Althea for quite some time and this collaboration is a logical next step for both companies in driving innovation in drug discovery. It will allow us to further strengthen our product development in many ways, and it will drive more future innovations.”
Questions about how our services can accelerate your research? Reach out to one of our experts today and we can provide you with tailored advice on getting started
Contact an Expert.png)
